GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pulmatrix Inc (NAS:PULM) » Definitions » Shiller PE Ratio

PULM (Pulmatrix) Shiller PE Ratio : (As of Apr. 01, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Pulmatrix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pulmatrix Shiller PE Ratio Historical Data

The historical data trend for Pulmatrix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmatrix Shiller PE Ratio Chart

Pulmatrix Annual Data
Trend Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pulmatrix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pulmatrix's Shiller PE Ratio

For the Biotechnology subindustry, Pulmatrix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmatrix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulmatrix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Pulmatrix's Shiller PE Ratio falls into.


;
;

Pulmatrix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Pulmatrix's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Pulmatrix's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.55/133.1571*133.1571
=-0.550

Current CPI (Dec. 2024) = 133.1571.

Pulmatrix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -160.000 99.621 -213.862
201506 -1,154.000 100.684 -1,526.195
201509 -68.000 100.392 -90.194
201512 -61.523 99.792 -82.093
201603 -76.000 100.470 -100.726
201606 -124.000 101.688 -162.374
201609 -42.000 101.861 -54.904
201612 -132.000 101.863 -172.553
201703 -42.000 102.862 -54.370
201706 -58.000 103.349 -74.728
201709 -44.000 104.136 -56.262
201712 -42.400 104.011 -54.281
201803 -47.800 105.290 -60.452
201806 -26.800 106.317 -33.566
201809 -20.600 106.507 -25.755
201812 -15.000 105.998 -18.843
201903 -14.800 107.251 -18.375
201906 -8.200 108.070 -10.104
201909 -3.600 108.329 -4.425
201912 -3.200 108.420 -3.930
202003 -4.600 108.902 -5.625
202006 -1.000 108.767 -1.224
202009 -6.200 109.815 -7.518
202012 -1.030 109.897 -1.248
202103 -1.780 111.754 -2.121
202106 -1.370 114.631 -1.591
202109 -2.910 115.734 -3.348
202112 -2.550 117.630 -2.887
202203 -1.510 121.301 -1.658
202206 -1.360 125.017 -1.449
202209 -1.450 125.227 -1.542
202212 -1.140 125.222 -1.212
202303 -1.220 127.348 -1.276
202306 -1.040 128.729 -1.076
202309 -1.030 129.860 -1.056
202312 -0.570 129.419 -0.586
202403 0.230 131.776 0.232
202406 -1.590 132.554 -1.597
202409 -0.710 133.029 -0.711
202412 -0.550 133.157 -0.550

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pulmatrix  (NAS:PULM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Pulmatrix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Pulmatrix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmatrix Business Description

Traded in Other Exchanges
Address
36 Crosby Drive, Suite 100, Bedford, MA, USA, 01730
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Executives
Peter Ludlum officer: Interim CFO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Margaret Wasilewski officer: Chief Medical Officer C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Anand Varadan director C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Todd Bazemore director C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Christopher Cabell director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Michelle Siegert officer: Vice President, Finance 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421
Richard P. Batycky director C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Robert Nelsen other: Former 10% owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Polaris Venture Partners Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Entrepreneurs' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners Special Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Partners V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Polaris Venture Management Co. V, L.l.c. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
Jonathan A Flint 10 percent owner 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451
Polaris Venture Management Co Iv Llc 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210